Wall Street analysts forecast that Vertex Pharmaceuticals (VRTX) will report quarterly earnings of $5.07 per share in its upcoming release, pointing to a year-over-year increase of 27.4%. It is anticipated that revenues will amount to $3.17 billion, exhibiting an increase of 8.8% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Vertex metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts predict that the 'Revenues by Product- Trikafta/Kaftrio' will reach $2.57 billion. The estimate indicates a change of -5.6% from the prior-year quarter.
The consensus estimate for 'Revenues by Product- Other product revenues' stands at $216.84 million. The estimate suggests a change of +13.4% year over year.
Analysts expect 'Geographic Revenues- United States' to come in at $1.87 billion. The estimate indicates a year-over-year change of +1.9%.
Based on the collective assessment of analysts, 'Geographic Revenues- Outside of the United States' should arrive at $1.25 billion. The estimate indicates a year-over-year change of +16.3%.
View all Key Company Metrics for Vertex here>>>
Vertex shares have witnessed a change of +3% in the past month, in contrast to the Zacks S&P 500 composite's -0.2% move. With a Zacks Rank #3 (Hold), VRTX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
